

U.S.S.N.: 09/700,354
Atty Dkt: IRVNO007C1P2REMARKS

Claims 57-80 were previously pending in this application. Remarks explaining the patentability of these claims were made in the Response filed November 20, 2003.

New claims 81-90 are added in this Supplemental Amendment to provide additional protection for the subject matter which the applicant regards as their invention, and which is of current commercial interest.

Upon entry of these amendments, claims 57-90 are pending in the application. Claims 57-61, 66, 72, 74-76, 78, and 80 to 90 are under examination. Claims 62-65, 67-71, 73, 77, and 79 are withdrawn from consideration, but subject to a request for rejoinder.

No new matter is introduced into the disclosure as a result of entering these amendments. Claims 81-84 and 86-89 are supported *inter alia* by claims 57, 58, and 59 as previously presented. With reference to claims 85 and 90, use of the proteins of the invention for reducing inflammation when administered to a subject who has septic shock, arthritis, or multiple sclerosis is described in the specification on page 25, lines 21-25. Accepted animal models for testing the anti-inflammatory activity of the proteins are provided on page 26, line 29 to page 27, line 15; and Example 8 (page 47 ff.).

Applicants respectfully submit that the new claims do not impose an undue burden on the Examiner, since SEQ ID NOS:1, 5, 6, 8, 9 and 10 have already been searched in this application and in the priority application (now U.S. Patent No. 6,593,456).

Further examination of the application including the new claims is respectfully requested.

USSN: 09/700,354
Any Dkt: IRVN007CIP2

In the event that the Examiner determines there are other matters to be addressed, applicants hereby request an interview by telephone.

In the event that the transmittal letter is separated from this document and the Patent Office determines that extensions or other relief is required and/or fees are due applicants, the Applicant petitions for any required relief, including extensions of time, and authorize the Commissioner to charge our Deposit Account No. 50-0815, Order Number IRVN-007CIP2, for any fees due in connection with the filing of this document. The Patent Office is not authorized to charge issue fees to our Deposit Account.


Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date:

Mar 2, 2004

By:


Carol L. Francis
Registration No. 36513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENT\IRVN (UC Irvine)\007cip2\Supplemental Amendment IRVN 007CIP2.doc